Stocks and InvestingStocks and Investing
Fri, January 21, 2022
Thu, January 20, 2022
Wed, January 19, 2022
Tue, January 18, 2022

Raghuram Selvaraju Maintained (URGN) at Strong Buy with Decreased Target to $34 on, Jan 18th, 2022


Published on 2024-10-27 19:18:01 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "UroGen Pharma Ltd." (URGN) at Strong Buy with Decreased Target from $50 to $34 on, Jan 18th, 2022.

Raghuram, nor any peers, have made any analyst calls on URGN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30